Anika Therapeutics (ANIK) EBITDA Margin (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of EBITDA Margin data on file, last reported at 18.26% in Q1 2026.

• EBITDA Margin for Q1 2026 came in at 18.26%, down 224.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.83% (up 3946.0% YoY), and the FY2025 annual result was 8.03%, up 3970.0% from the prior year.
• EBITDA Margin retreated to 18.26% in Q1 2026 per ANIK's latest filing, from 0.89% in the prior quarter.
• Over five years, EBITDA Margin peaked at 2151.74% in Q4 2023 and troughed at 98.8% in Q3 2024.
• A 5-year average of 115.74% and a median of 9.3% in 2022 frame the typical range for EBITDA Margin.
• The sharpest annual moves came in 2023 and 2024: EBITDA Margin jumped 201346 bps in 2023, then sank 222673 bps in 2024.
• A 5-year view of EBITDA Margin shows it stood at 138.28% in 2022, then jumped by 1456 bps to 2151.74% in 2023, then slumped by 103 bps to 74.99% in 2024, then soared by 101 bps to 0.89% in 2025, then tumbled by 2155 bps to 18.26% in 2026.
• Business Quant data shows ANIK's EBITDA Margin at 18.26% in Q1 2026, 0.89% in Q4 2025, and 9.03% in Q3 2025.